Naturista Store sold ADVANCE KING, labeled a supplement, containing undeclared dexamethasone, diclofenac, and methocarbamol; FDA calls it an unapproved, misbranded drug.
What happened
FDA reviewed https://naturistastore.com/ from Dec 2024 to February 2025 and obtained a sample of “ADVANCE KING,” which the website offered for sale in the United States. Laboratory analysis found the product contained undeclared dexamethasone, diclofenac, and methocarbamol. The product was labeled as a dietary supplement but marketed with claims to relieve pain and treat conditions such as sciatica, osteoarthritis, and gout.
What FDA found
The product’s labeling does not disclose that it contains dexamethasone, diclofenac, and methocarbamol.
FD&C Act §502(a), 21 U.S.C. 352(a); §201(n), 21 U.S.C. 321(n)The product is an unapproved new drug sold in interstate commerce without an FDA-approved application.
FD&C Act §§505(a), 301(d), 21 U.S.C. 355(a), 331(d)The product is a drug because its labeling claims it treats pain, sciatica, osteoarthritis, gout, and other conditions.
FD&C Act §201(g)(1)(B), 21 U.S.C. 321(g)(1)(B)The product is excluded from being a dietary supplement because it contains diclofenac and dexamethasone, which were approved as drugs before being marketed as supplements or food.
FD&C Act §201(ff)(3)(B)(i), 21 U.S.C. 321(ff)(3)(B)(i)Labeling presents ADVANCE KING as a natural supplement while concealing active drug ingredients, making it misleading.
FD&C Act §502(a), 21 U.S.C. 352(a)
What FDA wants
FDA asks Naturista Store to notify it in writing within 15 working days of the steps taken to correct the violations, prevent recurrence, and include supporting documents. If corrective action cannot be completed in that time, the company must state why and give a completion date.
Who should pay attention
- online retailers selling imported arthritis or pain supplements
- brands and distributors of NatuMex, Artri King, Royal Honey, or similar supplements
- consumers who bought ADVANCE KING or similar products
This is a summary. Read the original letter on fda.gov.